September 28, 2020

Significant biosimilar activities this week include:

  • 21 Sep 20, EU: Alexion announced it has received a positive opinion from the EU's CHMP for a new 100mg/mL formulation of Ultomiris® (ravulizumab).  The new formulation requires an infusion time of 0.4 hours to 1.3...

Significant biosimilar activities this week include:

  • At the beginning of March 2020, the UK High Court ruled filing errors in a Supplementary Protection Certificate (SPC) for Lucentis® (ranibizumab) have cut almost two years from Roche/Genentech's protection in the...

Please reload

Biosimilars bulletin 

October 4, 2020

Please reload

Search by tags